IPS-Integrated Project Services, LLC / WuXi BiologicsWuXiWuXi Biologics Sells Irish Vaccine Site to...WuXi Biologics has agreed to sell its Dundalk vaccine manufacturing facility to Merck, a move that will enhance asset efficiencies and allow the company to focus on CDMO services at its other global … more ➔
Orbis MedicinesOrbisOrbis Medicines secures €90m to advance...Orbis Medicines secures €90m in Series A funding to accelerate the development of oral macrocycle drugs, leveraging automated chemistry and machine learning. more ➔
pixabay.com - geraltSeasons GreetingsMerry Christmas and a Happy New YearThank you for a successful 2024! more ➔
SK BioscienceVaccinesSanofi expands collaboration with SK Biosc...In parallel with the expansion of its collaboration with SK Bioscience Co. Ltd, the French pharmaceutical company Sanofi SA has announced Phase III testing of its licensed pneumococcal conjugate vaccine … more ➔
wikioedia.org - Von http://web2.airmail.net/uthman/specimens/index.html, Gemeinfrei, https://commons.wikimedia.org/w/index.php?curid=841015FibrosisCough medicine reverses fibrosis in animal...Screening a library of 712 market-approved drugs, German researchers have found that a cough medicine most efficiently reduced incurable lung fibrosis in mice and in vitro. more ➔
Photys TherapeuticsPartnershipPhotys Therapeutics inks deal with Novo No...Novo Nordiks has licenced Photys Therapeutics PHICS platform to target a single cardiometabolic target. Photys got US$186m upfront. more ➔
DeepLife SASAI-guided screeningDeepLife raises US$10m in Series A financi...Generative AI specialist DeepLife SAS has raises US$10m in a Series A financing led by YZR Capital and Relyens Innovation Santé with participation from Beiersdorf Venture Capital, Prunay Group, and … more ➔
Wilfried Le Goff (INSERM, Sorbonne Université)ObesityMembrane target triggers inflammationResearchers at Sorbonne Paris have discovered that a membrane protein in adipocytes of obese mice and humans changes the lipid composition of adipose tissue macrophages rendering them more inflammatory … more ➔
Synaffix/LanzaADCsElevation Oncology Inc licences Synaffix B...Elevation Oncology Inc has inked a US$368m license agreement with Lonza subsidiary Synaffix BV under which Synaffix will link Elevation’s HER3 antibody seribantumab to a monomethyl auristatin E (MMAE) … more ➔
RSRTRNA editingRNA specialist ProQR Therapeutics NV bags...RNA editing specialist ProQR Therapeutics NV has deepened its collaboration with the Rett Syndrome Research Trust, which extented its funding of the preclinical MECP2 inhibitor AX-2402 to US$9.1m to … more ➔